the SmallCapReview mailing list
Is an emerging leader in social calendaring and social utility application
development. Eventure has recently Beta released its website with the purpose of
socializing one's calendar and creating a mobile-to-web "Events"
based communications platform.
The website's social calendaring platform
incorporates many of Eventure's technological innovations that extend into
an ad-hoc mobile-to-mobile "network feature" that allows users who
are attending an event to instantly connect with and share content with each
other based on their proximity to one another, while being guarded by the
application's sound privacy native settings.
Whether planning, inviting, attending, capturing or scrapboarding, Eventure truly redefines how one organizes life's most memorable moments.
For the first time ever, there’s a Social Calendar to use.
technology and innovation leader in the development of robotic cardiology
instrument navigation systems designed to enhance the treatment of
arrhythmias and coronary disease, as well as information management
solutions for the interventional lab.
With over 100 patents for use in a
hospital's interventional surgical suite, Stereotaxis helps physicians
around the world provide unsurpassed patient care with robotic precision and
safety, improved lab efficiency and productivity, and enhanced collaboration
of life-saving information.
Stereotaxis' core technologies are
the Niobe ES Remote Magnetic Navigation system, the Odyssey
portfolio of lab optimization, networking and patient information
management systems and the Vdrive Robotic Mechanical
Navigation system and consumables.
The core components of Stereotaxis
systems have received regulatory clearance in the U.S., Europe, Canada and
elsewhere. The V-Sono ICE catheter manipulator has received U.S.
clearance, and the V-Loop circular catheter manipulator is
currently in clinical trials in order to obtain clearance by the U.S. Food
and Drug Administration.
A biopharmaceutical company that engages in developing therapeutics for
various disease indications primarily in Canada. Its product candidates
include ELND005 (AZD-103), a Phase II clinical trial product for the
treatment of Alzheimers disease and neuropsychiatric disorders; TT-301 and
TT-302, which are in Phase I clinical trial for the treatment of rheumatoid
arthritis, Alzheimers disease, intracerebral hemorrhage, and traumatic brain
injury; and TT401/402, a Phase I clinical trial product to treat
The company also has a pipeline
of preclinical and clinical drug candidates for the treatment of
anti-inflammatory and metabolic indications. It has strategic collaborations
with Elan Pharma International Limited to develop and commercialize ELND005
(AZD-103); and Eli Lilly and Company.
A clinical-stage biopharmaceutical
company committed to discovering, developing and commercializing products
targeting inflammation, coagulopathies and disorders of the central nervous
The Company's most clinically
advanced product candidates, OMS302 for lens replacement surgery and OMS103HP
for arthroscopy, are derived from its proprietary PharmacoSurgery platform
designed to improve clinical outcomes of patients undergoing a wide range of
surgical and medical procedures.
Omeros has five clinical development